Anti-Angina Medication Selection Algorithm

First-Line Therapy Selection

The European Society of Cardiology recommends beta-blockers as the preferred first-line therapy for most patients with chronic coronary syndrome (CCS), particularly those with prior myocardial infarction, heart failure with reduced ejection fraction, hypertension, or atrial fibrillation 3
Calcium channel blockers (CCBs) are appropriate first-line therapy for patients with contraindications to beta-blockers, vasospastic angina, microvascular angina, or hypertension 1, 3
Short-acting nitrates are recommended for immediate relief of acute angina symptoms in all patients 1, 2

The European Heart Journal suggests that if symptoms are not adequately controlled with a beta-blocker or CCB alone, the combination of a beta-blocker with a dihydropyridine CCB should be considered 1, 2
When selecting combination therapy, consider avoiding combining non-dihydropyridine CCBs (verapamil, diltiazem) with beta-blockers due to risk of excessive bradycardia 2, 3

Long-acting nitrates or ranolazine should be considered as add-on therapy when symptoms persist despite beta-blockers and/or CCBs 1, 2
Nicorandil or trimetazidine may be considered as add-on therapy in patients with inadequate symptom control on beta-blockers and/or CCBs 2, 3
Ivabradine should be considered as add-on therapy specifically in patients with left ventricular systolic dysfunction, inadequate symptom control on other therapies, or heart rate >70 bpm despite beta-blocker therapy 2, 3

For patients with microvascular angina, ranolazine and trimetazidine are particularly effective 1, 3
For patients with vasospastic angina, dihydropyridine CCBs are first-line therapy, and nicorandil or nitrates can be added for better symptom control 3, 5

Beta-blockers are contraindicated in sick sinus syndrome, atrioventricular conduction disorders, and should be used with caution in peripheral arterial disease and chronic obstructive pulmonary disease 2
Nitrates are contraindicated in hypertrophic cardiomyopathy and co-administration with phosphodiesterase inhibitors 2

Beta-blockers should be titrated to achieve resting heart rate of 55-60 bpm for optimal antianginal effect 3
Long-acting nitrates require a daily "nitrate-free" interval of 10-12 hours to prevent tolerance 4

The selection of antianginal therapy should be guided by the patient's hemodynamic profile, comorbidities, and the underlying pathophysiological mechanism of angina 1, 3

Failing to provide adequate "nitrate-free" intervals when prescribing long-acting nitrates, leading to tolerance 4
Combining non-dihydropyridine CCBs with beta-blockers or ivabradine, which can cause excessive bradycardia 2, 3